IgG4 Production Against Adalimumab During Long Term Treatment of RA Patients (Q61640354)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22622790%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

title

IgG4 production against adalimumab during long term treatment of RA patients (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22622790%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

1 reference

Pauline A van Schouwenburg

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22622790%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

author name string

Michael Nurmohamed

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22622790%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Margreet Hart

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22622790%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Theo Rispens

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22622790%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Lucien Aarden

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22622790%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Diana Wouters

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22622790%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Gerrit Jan Wolbink

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22622790%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Charlotte L Krieckaert

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22622790%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

publication date

24 May 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22622790%20AND%20SRC:MED&resulttype=core&format=json

Journal of Clinical Immunology

2 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22622790%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

volume

32

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22622790%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22622790%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

page(s)

1000-1006

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22622790%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s10875-012-9705-0

2 February 2020

exact match

0 references

cites work

Open-label, pilot protocol of patients with rheumatoid arthritis who switch to infliximab after an incomplete response to etanercept: the opposite study

1 reference

12 December 2020

Serologic aspects of IgG4 antibodies. II. IgG4 antibodies form small, nonprecipitating immune complexes due to functional monovalency

1 reference

12 December 2020

Current status of monoclonal antibody therapy for the treatment of inflammatory bowel disease

1 reference

12 December 2020

Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis

1 reference

12 December 2020

Immunoglobulin G4: an odd antibody

1 reference

12 December 2020

Fel d 1-specific IgG antibodies induced by natural exposure have blocking activity in skin tests

1 reference

12 December 2020

Subclass typing of IgG antibodies formed by grass pollen-allergic patients during immunotherapy

1 reference

12 December 2020

Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up

1 reference

12 December 2020

Psoriatic arthritis management update - biotherapeutic options.

1 reference

12 December 2020

What is IgG4? A review of the biology of a unique immunoglobulin subtype

1 reference

12 December 2020

The apparent monovalency of human IgG4 is due to bispecificity

1 reference

12 December 2020

Immunoglobulin Subclasses in Patients with Neutralizing and Nonneutralizing Antibodies Against IFN-β1b

1 reference

12 December 2020

The differential ability of human IgG1 and IgG4 to activate complement is determined by the COOH-terminal sequence of the CH2 domain

1 reference

12 December 2020

Anti-Inflammatory Activity of Human IgG4 Antibodies by Dynamic Fab Arm Exchange

1 reference

12 December 2020

A novel method for the detection of antibodies to adalimumab in the presence of drug reveals “hidden” immunogenicity in rheumatoid arthritis patients

1 reference

12 December 2020

IgG subclasses of anti-FVIII antibodies during immune tolerance induction in patients with hemophilia A.

1 reference

12 December 2020

Immunogenicity of anti-tumor necrosis factor antibodies-toward improved methods of anti-antibody measurement

1 reference

12 December 2020

Grass pollen immunotherapy induces mucosal and peripheral IL-10 responses and blocking IgG activity.

1 reference

12 December 2020

Differential effect of drug interference in immunogenicity assays

1 reference

12 December 2020

Relationship between the clinical response to adalimumab treatment and serum levels of adalimumab and anti-adalimumab antibodies in patients with psoriatic arthritis

1 reference

12 December 2020

Monitoring allergen immunotherapy of pollen-allergic patients: the ratio of allergen-specific IgG4 to IgG1 correlates with clinical outcome

1 reference

12 December 2020

Serologic aspects of IgG4 antibodies. I. Prolonged immunization results in an IgG4-restricted response

1 reference

12 December 2020

Antibodies to constant domains of therapeutic monoclonal antibodies: anti-hinge antibodies in immunogenicity testing

1 reference

12 December 2020

Monitoring patients treated with anti-TNF-alpha biopharmaceuticals: assessing serum infliximab and anti-infliximab antibodies

1 reference

12 December 2020

Decreased clinical response to adalimumab in ankylosing spondylitis is associated with antibody formation

1 reference

12 December 2020

Influence of Trough Serum Levels and Immunogenicity on Long-term Outcome of Adalimumab Therapy in Crohn's Disease

1 reference

12 December 2020

Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis

1 reference

12 December 2020